SEC allows Bharat Biotech to unblind all participants above 45 years
Updated:
Updated:
Recommendation based on the availability of vaccines under the immunisation programme
Share Article
AAA
Bharat Biotech intends to carry out a phase 3 trial in a cohort in Brazil.
| Photo Credit:
REUTERS
Recommendation based on the availability of vaccines under the immunisation programme
On March 24, the Subject Expert Committee (SEC) permitted Bharat Biotech to unblind all “participants of age group of more than 45 years and offer to administer the vaccine free of cost as and when they become eligible for the vaccine in the national programme”. The Committee recommended that the company unblind the participants as “vaccines [including Covaxin] are [already] available under the immunisation programme, and therefore all the eligible age groups under the immunisation programme should be permitted for unblinding for vaccination”.
No proof COVID second wave due to virus variants, but it is possible: Virologist Shahid Jameel
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
N440K variant detected in Punjab, role behind surge under probe
ibtimes.co.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ibtimes.co.in Daily Mail and Mail on Sunday newspapers.